Research feed
Recently published diabetes studies added to Dediabetes, summarized and organized by intervention and outcome.
Sorted by publication date. Some studies may have been added to Dediabetes later.
Need advanced filters? Search the full archive.
This study evaluated the effectiveness of insulin glargine-lixisenatide fixed-ratio combination (iGlarLixi) in individuals with type 2 diabetes. It found significant improvements in body weight, BMI, and insulin dosage compared to multiple daily injections (MDI).
This study investigated the potential of natural product-based treatments for type 2 diabetes and cardiovascular disease, finding significant reductions in various health markers.
This randomized trial tested an early Mediterranean diet intervention during pregnancy. Women assigned to extra virgin olive oil and pistachios had fewer gestational diabetes diagnoses and better several maternal and neonatal outcomes than women given standard low-fat diet advice.
This 12-week trial tested oxygen-enriched ELO water as an add-on therapy in adults with type 2 diabetes. HbA1c fell modestly in the ELO group, especially by week 6 compared with placebo, but fasting glucose and body weight did not clearly improve.
This cluster-randomized trial tested a community-based peer-support lifestyle program in 1,007 high-risk Indian adults. The program improved diet, reduced alcohol use, and enhanced physical functioning, but the 14.9% vs 17.1% reduction in diabetes incidence was not statistically significant.
This trial tested whether adults with prediabetes could start and maintain resistance training. After a supervised 3-month training phase, about one-third of participants were no longer prediabetic, and this was mostly maintained through 15 months. Extra social-cognitive support did not outperform lower-contact standard care.
This study evaluated the effects of a multi-species synbiotic preparation on metabolic profiles in elderly patients with type 2 diabetes and high cardiovascular risk, finding significant reductions in weight, cholesterol, and glucose levels.
This small trial analysis tested daily tadalafil in people with type 2 diabetes. Tadalafil lowered some blood biomarkers related to amyloid metabolism and astroglial activation, but it did not change several other brain-related biomarkers.
This study tested monthly physiotherapist-led exercise guidance supported by wearable device feedback in people with type 2 diabetes, including diabetic kidney disease. Over six months, the intervention group walked farther and had lower HbA1c than the standard care group, while kidney filtration did not clearly change.
Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.
